Medigene AG (FRA:MDG1) EBIT: €-15.31 Mil (TTM As of Jun. 2024)


FRA:MDG1 Medigene AG FRA:MDG1
12 GF Score
Price €0.02
View Full Analysis

What is Medigene AG EBIT?

Medigene AG FRA:MDG1 -10.20% 12 EBIT is €-15.31 Mil as of Jun. 2024. GuruFocus rates FRA:MDG1 with a GF Score™ of 12/100.

Medigene AG's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-6.64 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-15.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medigene AG's annualized ROC % for the quarter that ended in Jun. 2024 was -68.01%. Medigene AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -408.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medigene AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 136.46%.

Medigene AG  (FRA:MDG1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medigene AG's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-13.28 * ( 1 - 0% )/( (19.75 + 19.301)/ 2 )
=-13.28/19.5255
=-68.01 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=31.716 - 1.008 - ( 16.674 - max(0, 7.179 - 18.137+16.674))
=19.75

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=28.81 - 0.411 - ( 14.024 - max(0, 6.532 - 15.63+14.024))
=19.301

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medigene AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.28/( ( (3.438 + max(-4.802, 0)) + (3.057 + max(-3.991, 0)) )/ 2 )
=-13.28/( ( 3.438 + 3.057 )/ 2 )
=-13.28/3.2475
=-408.93 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.416 + 0 + 1.047) - (1.008 + 0 + 5.257)
=-4.802

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.499 + 0 + 1.107) - (0.411 + 0 + 5.186)
=-3.991

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medigene AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-15.311/-11.220
=136.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG EBIT Related Terms

Medigene AG EBIT Historical Data

* Premium members only.

The historical data trend for Medigene AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG EBIT Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.47 -27.98 -9.92 -8.72 -16.04

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.61 -23.33 -7.37 -8.67 -6.64

FRA:MDG1 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Medigene AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medigene AG's EV-to-EBIT falls into.


FRA:MDG1
12GF Score
Medigene AG FRA:MDG1
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-15.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-15.31 Mil mean?
Medigene AG (FRA:MDG1) has a EBIT of €-15.31 Mil as of Jun. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medigene AG.
Is Medigene AG's EBIT too high?
Medigene AG's current EBIT is €-15.31 Mil. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's EBIT compare to VRTX and REGN?
Medigene AG's EBIT of €-15.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medigene AG. Medigene AG's current EBIT is €-15.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (FRA:MDG1) has a current EBIT of €-15.31 Mil. The current EBIT is €-15.31 Mil. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medigene AG (FRA:MDG1), the current EBIT is €-15.31 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for FRA:MDG1

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price